Search

In 2025, MSK was again ranked among the top organizations with the greatest number of highly cited scientific researchers worldwide, according to the annual list of Highly Cited Researchers, published by the Institute for Scientific Information at Clarivate.

… Wednesday, November 12, 2025 In science, having your research cited by other researchers is one of the most public signs of your influence — a mark that a study has become part of the foundation others are building upon. This year, Memorial Sloan Kettering Cancer Center (MSK) was again ranked among the

Meet the 11 new faculty members that have joined the Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences.

… Thursday, July 15, 2021 The Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences has welcomed 11 new faculty members since June 2020. These outstanding scientists, who are at the forefront of biomedical research, join a community of colleagues committed to fostering a robust and exciting

Laboratory research shows how it may be possible to develop an immunotherapy-based approach for treating aggressive forms of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

… Wednesday, April 23, 2025 The blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are extremely challenging to treat. While advances in immunotherapy have cured many patients with other blood cancers, they haven’t been successful for AML and MDS. Together, these diseases kill

Read our key takeaways from the second half of the American Association for Cancer Research’s 2019 annual meeting.

… Monday, April 1, 2019 Summary Memorial Sloan Kettering scientists are presenting data from more than 100 studies at the American Association for Cancer Research’s 2019 annual meeting, held this year in Atlanta. Below is part two of our research roundup. Read part one of our coverage. Early Detection

Learn about the Marie-Josée Kravis Fellowship in Quantitative Biology, a two-year postdoctoral fellowship that aims to build a new generation of skilled quantitative biologists who specialize in cancer.

… Wednesday, April 19, 2023 These days Sneha Mitra, PhD , spends a lot of time thinking about T cells — a type of white blood cell that helps protect the body from infection and cancer. A postdoctoral fellow at the Sloan Kettering Institute , Dr. Mitra is working to understand how the interactions and

Breakthrough findings were presented at the 2022 ASCO Annual Meeting and published in The New England Journal of Medicine today by researchers at Memorial Sloan Kettering Cancer Center (MSK) confirming a clinical complete response in all 14 patients who received the immunotherapy treatment dostarlimab as a first-line treatment for mismatch repair-deficient (MMRd) locally advanced rectal cancer. This new approach of “immunoablative” therapy uses immunotherapy to replace surgery, chemotherapy and radiation to remove cancer.

… Sunday, June 5, 2022 Some members of the MSK team behind the groundbreaking research at the American Society of Clinical Oncology, June 2022 (l to r): Dr. Luis Diaz, Dr. Andrea Cercek, Jenna Sinopoli, clinical trials nurse, Jill Weiss, clinical research supervisor, Melissa Lumish, clinical fellow. Some

Researchers have found that the genetic changes that cause pediatric leukemia are different from those that lead to leukemia in adults.

… Monday, February 18, 2019 Summary The finding that the mutations behind certain pediatric blood cancers are different from those that trigger leukemia in adults helps explain why some leukemias in children are so difficult to treat. A study exploring the genetic landscape of leukemia in children has

MSK employees celebrate the 2020 African American Day Parade with a watch party.

… Wednesday, January 1, 2020 Julia Ramirez was looking at her computer screen with tears in her eyes, and her 6-year-old son, Teo, wanted to know why. She tried to explain the deep emotions welling up as she viewed this year’s African American Day Parade at a Zoom watch party with her Memorial Sloan Kettering

New MSK research finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of Foxp3; shows how cancer develops resistance to antibody-drug conjugates; develops a new system to help make gene editing safer and more reliable; and shows provider billing margin doesn’t drive cancer treatment selection.

… Thursday, November 20, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of Foxp3; shows how cancer develops resistance to antibody-drug conjugates; develops a new system to help make gene editing

The insights lay the groundwork for earlier diagnosis and better treatment of the disease.

… Wednesday, February 3, 2021 Summary Both genes and environment are necessary to trigger pancreatic cancer development. A new study from the  Sloan Kettering Institute  at Memorial Sloan Kettering explains why. Like weeds sprouting from cracks in the pavement, cancer often forms in sites of tissue damage